Table 1 Mean and standard deviation of apoptotic MCF-7 cells after 4 and 24 h exposure at three concentrations of compound 1 (11,13-diidrozaluzanin C) and 2 (Gochnatiolide C) associated with doxorubicin

Control

4.00 ± 1.87^a

10.75 ± 2.86^a

p > 0,05

Doxorrubicin (D) - 0.3 μM

33.25 ± 5.34^b

61.75 ± 10.82^b

*

Compound 1 – 14 μM

16.00 ± 1.87^c

23.25 ± 3.83^b

*

Compound 1–28 μM

24.25 ± 5.71^b,c

33.5 ± 3.77^c

p > 0,05

Compound 1–56 μM

21.5 ± 4.83^b,c

17.5 ± 2.95^a

p > 0,05

Compound 1–14 μM + D 0.3 μM

47.00 ± 6.07^b

47.25 ± 5.21^b

p > 0,05

Compound1 - 28 μM+ D 0.3 μM

39.75 ± 8.19^b

51.25 ± 10.2^b

p > 0,05

Compound1 - 56 μM + D 0.3 μM

52.25 ± 9.8^b

31.5 ± 4.6^c

*

Compound 2–0.5 μM

24.50 ± 2.69^b

40.00 ± 4.94^c

*

Compound 2–1.0 μM

41.75 ± 10.05^b,c

51.50 ± 7.69^b

p > 0,05

Compound 2–2.0 μM

53.25 ± 6.13^c

60.25 ± 10.03^b

p > 0,05

Compound 2–0.5 μM + D 0.3 M

31.25 ± 4.20^b

31.25 ± 5.76^c

p > 0,05

Compound 2–1.0 μM + D 0.3 μM

40.00 ± 5.43^b

45.25 ± 4.14^c

p > 0,05

Compound 2–2.0 μM + D 0.3 μM

46.25 ± 4.44^b,c

62.00 ± 7.51^b

*